IQVIA Holdings Inc. (IQV)
| Market Cap | 35.28B |
| Revenue (ttm) | 15.32B |
| Net Income (ttm) | 1.41B |
| Shares Out | 181.50M |
| EPS (ttm) | 7.62 |
| PE Ratio | 25.51 |
| Forward PE | 16.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,390,562 |
| Open | 191.35 |
| Previous Close | 191.33 |
| Day's Range | 190.49 - 194.42 |
| 52-Week Range | 187.62 - 261.73 |
| Beta | 1.51 |
| Analysts | Buy |
| Price Target | 256.60 (+32.01%) |
| Earnings Date | Oct 31, 2024 |
About IQV
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to ge... [Read more]
Financial Performance
In 2023, IQVIA Holdings's revenue was $14.98 billion, an increase of 3.98% compared to the previous year's $14.41 billion. Earnings were $1.36 billion, an increase of 24.47%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for IQV stock is "Buy." The 12-month stock price forecast is $256.6, which is an increase of 32.01% from the latest price.
News
IQVIA CFO Ron Bruehlman to Speak at the UBS Global Healthcare Conference on November 13, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the UBS ...
IQVIA Holdings Inc. (IQV) Q3 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV) Q3 2024 Results Conference Call October 31, 2024 9:00 AM ET Company Participants Kerri Joseph - Senior Vice President, Investor Relations & Treasury Ari Bousbib - Chair...
IQVIA lowers annual revenue forecast amid trial delays
Contract research firm IQVIA lowered its annual revenue forecast on Thursday, due to delays in two clinical trials as one of its clients faces logistical challenges.
IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the...
IQVIA to Announce Third-Quarter 2024 Results on October 31, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. Th...
IQVIA Announces IQVIA AI Assistant, Powered by IQVIA Healthcare-grade AI™
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healt...
IQVIA AI Solution Receives 2024 Frost & Sullivan Global Customer Value Leadership Award
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, to...
Contract Research Giant IQVIA's Data Assets Are Biggest Differentiator, Provides Best Exposure To AI And Data Opportunities: Analyst
RBC Capital Markets initiated coverage on IQVIA Holdings Inc. IQV, noting the company's biggest differentiator is its data assets. The analyst says IQVIA is the largest global contract research organi...
Signant Health expands availability of its eClinical solutions by joining IQVIA One Home for Sites initiative
PHILADELPHIA , Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced an...
IQVIA CFO Ron Bruehlman to Speak at the Morgan Stanley Annual Global Healthcare Conference on September 4, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) announced today that Ron Bruehlman, executive vice president and chief financial officer, will speak at the Morg...
Reiterating Buy On IQVIA After Q2 Earnings
IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and incre...
These Analysts Boost Their Forecasts On IQVIA After Better-Than-Expected Earnings
IQVIA Holdings Inc IQV posted better-than-expected second-quarter earnings on Monday.
IQVIA Stock Pops After It Beats Q2 Earnings Estimates
IQVIA Holdings (IQV) beat second-quarter earnings expectations and raised its full-year outlook on Monday, sending shares higher.
IQVIA Holdings Inc. (IQV) Q2 2024 Earnings Call Transcript
IQVIA Holdings Inc. (NYSE:IQV) Q2 2024 Earnings Conference Call July 22, 2024 9:00 AM ET Company Participants Kerri Joseph - SVP, IR & Treasury Ari Bousbib - Chairman & CEO Ron Bruehlman - EVP & CFO ...
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings
IQVIA Holdings Inc IQV reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.
IQVIA raises annual profit forecast on improving demand for analytics services
Contract research firm IQVIA Holdings raised its forecast for full-year profit on Monday, banking on strength in demand for its healthcare data and analytics services.
IQVIA Reports Second-Quarter 2024 Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the li...
IQVIA Named a Leader in Medical Affairs and Regulatory Operations by Everest Group
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV) today announces that a leading, independent research firm, Everest Group, has recognized IQVIA as a Leader in its Life Sciences Regulat...
IQVIA to Announce Second-Quarter 2024 Results on July 22, 2024
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its second-quarter 2024 financial results before the market opens on Monday, July 22, 2024. The IQ...
IQVIA's SmartSolve® eQMS Wins 2024 MedTech Breakthrough Award “Best Use of Artificial Intelligence in Healthcare”
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions, and clinical research services to the life sciences industry,...
IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA (NYSE:IQV) today announced the launch of One Home for Sites™, a new technology platform that acts as a single sign-on and a single dashboard for th...
IQVIA Institute: Innovative Therapies and Strong Pipeline to Combat Rise in Cancer Diagnoses
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--As cancer incidence continues to rise, it's being met by wider use of innovative therapies and a robust pipeline of new drugs, according to a new report ...
Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings
The Investment Committee give you their top stocks to watch for the second half.
IQVIA: Long-Term Compounder Throwing Off Free Cash Flow
There have been numerous positive updates to IQVIA Holdings' fundamental economics since January 2023. It produced strong Q1 2024 earnings, with growth observed in all segments. Increasing returns fro...
U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline, Says IQVIA Institute
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Overall spending in the U.S. market for medicines grew by 2.5% and reached $435Bn in 2023. Excluding the contribution from COVID-19 vaccines and therapeu...